TET vs. VCT, ELM, ESNT, SYNT, SCPA, ZTF, IOF, ITX, WCH, and DCTA
Should you be buying Treatt stock or one of its competitors? The main competitors of Treatt include Victrex (VCT), Elementis (ELM), Essentra (ESNT), Synthomer (SYNT), Scapa Group (SCPA), Zotefoams (ZTF), Iofina (IOF), Itaconix (ITX), Wilmcote Holdings plc (WCH.L) (WCH), and Directa Plus (DCTA). These companies are all part of the "specialty chemicals" industry.
Victrex (LON:VCT) and Treatt (LON:TET) are both small-cap basic materials companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk, community ranking and valuation.
Victrex has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Treatt has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.
Victrex has a net margin of 10.81% compared to Victrex's net margin of 7.42%. Victrex's return on equity of 8.07% beat Treatt's return on equity.
In the previous week, Treatt had 2 more articles in the media than Victrex. MarketBeat recorded 3 mentions for Treatt and 1 mentions for Victrex. Victrex's average media sentiment score of 0.51 beat Treatt's score of 0.00 indicating that Treatt is being referred to more favorably in the news media.
96.4% of Victrex shares are held by institutional investors. Comparatively, 66.5% of Treatt shares are held by institutional investors. 1.6% of Victrex shares are held by company insiders. Comparatively, 13.6% of Treatt shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Victrex pays an annual dividend of GBX 60 per share and has a dividend yield of 4.7%. Treatt pays an annual dividend of GBX 8 per share and has a dividend yield of 1.6%. Victrex pays out 17,142.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Treatt pays out 4,444.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Victrex received 348 more outperform votes than Treatt when rated by MarketBeat users. However, 68.83% of users gave Treatt an outperform vote while only 63.77% of users gave Victrex an outperform vote.
Victrex has higher revenue and earnings than Treatt. Treatt is trading at a lower price-to-earnings ratio than Victrex, indicating that it is currently the more affordable of the two stocks.
Victrex currently has a consensus price target of GBX 1,746.67, suggesting a potential upside of 35.61%. Treatt has a consensus price target of GBX 655, suggesting a potential upside of 31.00%. Given Treatt's higher probable upside, research analysts plainly believe Victrex is more favorable than Treatt.
Summary
Victrex beats Treatt on 11 of the 19 factors compared between the two stocks.
Get Treatt News Delivered to You Automatically
Sign up to receive the latest news and ratings for TET and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TET and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
